(19)
(11) EP 3 373 919 A1

(12)

(43) Date of publication:
19.09.2018 Bulletin 2018/38

(21) Application number: 16865052.1

(22) Date of filing: 10.11.2016
(51) International Patent Classification (IPC): 
A61K 31/00(2006.01)
A61P 35/02(2006.01)
 A61P 35/00(2006.01)
C12Q 1/68(2018.01)
(86) International application number:
PCT/US2016/061444
(87) International publication number:
WO 2017/083592 (18.05.2017 Gazette 2017/20)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 11.11.2015 US 201562254109 P

(71) Applicants:
  • Celator Pharmaceuticals, Inc.
    Ewing, NJ 08628 (US)
  • Oregon Health & Science University
    Portland, OR 97201 (US)

(72) Inventors:
  • GORDON, Max
    Portland, OR 97239 (US)
  • TARDI, Paul
    Surrey, British Columbia V3S 1S4 (CA)
  • TYNER, Jeffrey
    Portland, OR 97221 (US)
  • MAYER, Lawrence
    North Vancouver, BC V7J 3M4 (CA)

(74) Representative: V.O. 
P.O. Box 87930 Carnegieplein 5
2508 DH Den Haag
2508 DH Den Haag (NL)

   


(54) ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA